Literature DB >> 32777336

Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas.

Grace Lee1, Nayan Lamba2, Andrzej Niemierko2, Daniel W Kim2, Paul H Chapman3, Jay S Loeffler2, William T Curry3, Robert L Martuza3, Kevin S Oh2, Fred G Barker3, Helen A Shih4.   

Abstract

PURPOSE: The optimal timing of adjuvant radiation therapy (RT) in the management of atypical meningiomas remains controversial. We compared the outcomes of atypical meningiomas managed with upfront adjuvant RT versus postoperative surveillance. METHODS AND MATERIALS: Patients with intracranial atypical meningiomas who underwent resection between 2000 and 2015 at a single institution were identified. Patients receiving adjuvant RT (n = 51), defined as RT within the first year of surgery before tumor progression/recurrence (P/R), were compared with those undergoing initial surveillance (n = 179). The primary endpoints were radiographic evidence of P/R and time to P/R from surgery.
RESULTS: A total of 230 patients were identified. Fifty-one (22%) patients received upfront adjuvant RT, and 179 (78%) underwent surveillance. Compared with the surveillance group, patients who received adjuvant RT had larger tumors (5.2 cm vs 4.6 cm; P = .04), were more likely to have undergone subtotal resection (65% vs 26%; P < . 01), and more often had bone invasion (18% vs 7%; P = .02). On multivariable analysis, receipt of adjuvant RT was associated with a lower risk of P/R compared with surveillance (hazard ratio, 0.21; 95% confidence interval, 0.11-0.41; P < .01). Patients who initially underwent surveillance and then received salvage RT at time of P/R had a shorter median time to local progression after RT compared with patients who developed local P/R after upfront adjuvant RT (19 vs 64 months, respectively; P < . 01).
CONCLUSION: Upfront adjuvant RT was associated with improved local control in atypical meningiomas irrespective of extent of initial resection compared with surveillance. Early adjuvant RT should be strongly considered after gross total resection of atypical meningiomas.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32777336     DOI: 10.1016/j.ijrobp.2020.08.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Histopathological predictors of progression-free survival in atypical meningioma: a single-center retrospective cohort and meta-analysis.

Authors:  Min-Sung Kim; Se-Woong Chun; Yun-Sik Dho; Youngbeom Seo; Joo Ho Lee; Jae Kyung Won; Jin Wook Kim; Chul-Kee Park; Sung-Hye Park; Yong Hwy Kim
Journal:  Brain Tumor Pathol       Date:  2022-01-15       Impact factor: 3.298

2.  Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience.

Authors:  Collin L Kent; Yvonne M Mowery; Olayode Babatunde; Ato O Wright; Ian Barak; Frances McSherry; James E Herndon; Allan H Friedman; Ali Zomorodi; Katherine Peters; Annick Desjardins; Henry Friedman; William Sperduto; John P Kirkpatrick
Journal:  Adv Radiat Oncol       Date:  2021-12-24

3.  Adjuvant Radiotherapy Versus Surveillance for Grade 2 Intracranial Meningiomas: A Multi-Institutional Propensity Score-Matched Study.

Authors:  Hwa Kyung Byun; Won Ick Chang; Joo Ho Lee; Chul-Kee Park; In Ah Kim; Chae-Yong Kim; Jaeho Cho; Eui Hyun Kim; Jong Hee Chang; Seok-Gu Kang; Ju Hyung Moon; Sang Hyung Lee; Jason Joon Bock Lee; Il Han Kim; Chang-Ok Suh; Chan Woo Wee; Hong In Yoon
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

Review 4.  Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis.

Authors:  Se-Woong Chun; Kyung Min Kim; Min-Sung Kim; Ho Kang; Yun-Sik Dho; Youngbeom Seo; Jin Wook Kim; Yong Hwy Kim; Chul-Kee Park
Journal:  Radiat Oncol       Date:  2021-02-17       Impact factor: 3.481

5.  Postoperative Adjuvant Radiotherapy in Atypical Meningioma Patients: A Meta-Analysis Study.

Authors:  Dengpan Song; Dingkang Xu; Hongjie Han; Qiang Gao; Mingchu Zhang; Fang Wang; Guoqing Wang; Fuyou Guo
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

6.  Multisession radiosurgery for grade 2 (WHO), high risk meningiomas. A phase II clinical trial.

Authors:  Marcello Marchetti; Valentina Pinzi; Cecilia Iezzoni; Sara Morlino; Irene Tramacere; Elena De Martin; Irene Cane; Laura Fariselli
Journal:  J Neurooncol       Date:  2022-04-04       Impact factor: 4.506

7.  DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case-Control Study.

Authors:  Matthias Millesi; Alice Senta Ryba; Johannes A Hainfellner; Thomas Roetzer; Anna Sophie Berghoff; Matthias Preusser; Gerwin Heller; Erwin Tomasich; Felix Sahm; Karl Roessler; Stefan Wolfsberger
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

Review 8.  Bone Invasive Meningioma: Recent Advances and Therapeutic Perspectives.

Authors:  Hajime Takase; Tetsuya Yamamoto
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

Review 9.  Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues.

Authors:  Lorenzo Vagnoni; Sami Aburas; Martina Giraffa; Ivana Russo; Vito Chiarella; Sergio Paolini; Paolo Tini; Giuseppe Minniti
Journal:  Neurosurg Rev       Date:  2022-06-04       Impact factor: 2.800

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.